Quince Therapeutics (NASDAQ:QNCX) Cut to Market Perform at Citizens Jmp

Quince Therapeutics (NASDAQ:QNCX) was downgraded by research analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating in a research report issued on Friday.

Several other brokerages also recently commented on QNCX. Weiss Ratings restated a “sell (e+)” rating on shares of Quince Therapeutics in a research report on Monday, December 29th. Citigroup lowered Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday. Finally, D. Boral Capital restated a “buy” rating and set a $5.00 price objective on shares of Quince Therapeutics in a research report on Thursday. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Quince Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Quince Therapeutics Price Performance

Quince Therapeutics stock opened at $0.27 on Friday. The stock’s fifty day moving average price is $3.29 and its two-hundred day moving average price is $2.26. The firm has a market cap of $15.03 million, a PE ratio of -0.22 and a beta of 1.15. Quince Therapeutics has a one year low of $0.23 and a one year high of $4.55.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). Sell-side analysts expect that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Quince Therapeutics

Large investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in shares of Quince Therapeutics during the second quarter worth about $37,000. GSA Capital Partners LLP increased its holdings in Quince Therapeutics by 158.0% in the third quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock valued at $142,000 after purchasing an additional 53,417 shares during the period. Bridgeway Capital Management LLC lifted its holdings in Quince Therapeutics by 20.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock worth $212,000 after buying an additional 22,200 shares during the period. Rockefeller Capital Management L.P. bought a new stake in shares of Quince Therapeutics in the 2nd quarter valued at about $280,000. Finally, Union Square Park Capital Management LLC grew its position in shares of Quince Therapeutics by 86.0% in the 3rd quarter. Union Square Park Capital Management LLC now owns 224,746 shares of the company’s stock valued at $366,000 after buying an additional 103,889 shares during the last quarter. 30.75% of the stock is currently owned by institutional investors.

Key Quince Therapeutics News

Here are the key news stories impacting Quince Therapeutics this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and a $5.00 price target, signaling at least one analyst sees upside if the company can redeploy assets or secure new programs. Analyst Note
• Neutral Sentiment: Quince presented previously published long‑term safety data for eDSP at the British Paediatric Neurology Association meeting on Jan. 28 — useful context on tolerability but not sufficient to sustain the program after the Phase 3 outcome. Safety Data Presentation
• Neutral Sentiment: Trading was repeatedly halted late in the session (multiple LULD pauses and a “News pending” halt) as the market awaited and then digested the company’s Phase 3 announcement; these halts magnified intraday volatility.
• Negative Sentiment: Topline Phase 3 results were reported as negative, and Quince said it is ending development of eDSP — eliminating the company’s lead program and near‑term path to revenue. This is the primary reason for the steep share decline. Phase 3 Failure Report
• Negative Sentiment: Market commentary and press coverage emphasize the program termination and the stock’s >90% intraday drop; investors should expect severe dilution risk, limited near‑term pipeline value, and possible questions about the company’s cash runway and strategic alternatives. Program Termination Coverage
• Negative Sentiment: News aggregators and health outlets summarized why QNCX collapsed today — reinforcing negative sentiment and reducing likelihood of a quick rebound absent new assets, financing, or a strategic transaction. Market Reaction Summary

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.